Release date: October 12, 2020 Expiration date: October 12, 2021 Estimated time to complete activity: 60 minutes

PROGRAM OVERVIEW

Despite an increased understanding of inflammatory bowel diseases (IBD) pathophysiology and the introduction of corresponding targeted treatments with the potential to alter the disease’s natural history, clinical and endoscopic remission remain elusive for many patients. Several factors contribute to suboptimal outcomes, including an entrenched treatment paradigm that frequently results in prolonged use of ineffective medications, uncertainty about the safety and efficacy of medications, systemic barriers, and access challenges. In order to effectively treat IBD, gastroenterologists and the multidisciplinary IBD team of clinicians need strong foundational knowledge of the broad range of therapeutic agents licensed for the induction and maintenance of disease control, and how to individualize their use for any given patient. Education is necessary to ensure that clinicians who manage patients with IBD are up-to-date on current management strategies, including the use of objective measures such as mucosal healing and deep remission; new and emerging therapies, particularly novel mechanisms of action and safety profiles; and recent data from clinical trials. Clinicians must be knowledgeable regarding the benefits of early intervention, top-down versus step-up approaches, strategies for attaining remission and reducing healthcare costs, and new treat-to-target recommendations for management. This program will reduce these gaps through a conversational-style venue that fosters deeper educational impact and ultimately improves patient care.

FACULTY

Aline Charabaty Pishvaian, MD Associate Professor of Medicine Johns Hopkins School of Medicine Clinical Director, GI Division Director, IBD Center Sibley Memorial Hospital Washington, District of Columbia Amar Naik, MD Associate Professor of Medicine Director, Inflammatory Bowel Disease Program Regional Medical Director, Nutrition Services Division of Gastroenterology Loyola University Medical Center Hinsdale, Illinois

TARGET AUDIENCE

This educational initiative has been designed for all members involved in the IBD-care continuum. Of those that will derive the most benefit from this program are gastroenterologists, gastroenterologists in training, surgeons, subspecialists including dieticians and psychologists, nurse practitioners, physician’s assistants, nurses, and other healthcare team members involved in or interested in the care of patients with IBD.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants will be able to:

Outline current approaches and guideline-directed strategies for the management of IBD
Analyze challenging patient cases to identify alternate clinical approaches and enhance patient outcomes for IBD
Illustrate the importance of patient-centered care in addressing burdens associated with IBD

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of October 12, 2020 through October 12, 2021, participants must:

Read the learning objectives and faculty disclosures
Complete the pretest
Study the educational activity
Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 100%.

MEDIA

Internet

ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Integrity Continuing Education and Monday Night IBD. Integrity Continuing Education is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION

Live Participation on October 12, 2020: Integrity Continuing Education, Inc. designates this live material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Participation from October 13, 2020 – October 12, 2021: Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or info@integrityce.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: Aline Charabaty Pishvaian, MD Consulting Fees: AbbVie, Janssen, Takeda Speakers’ Bureaus: AbbVie, Takeda Amar Naik, MD Consulting Fees: AbbVie, Takeda Speakers’ Bureaus: AbbVie, Takeda, Pfizer, Inc. The Integrity Continuing Education, Inc. planners/managers do not have any conflicts of interest to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)

Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS

Plug-in: Adobe^® Flash^® Player 10

Adobe^® Flash^® Player 10 plug-in should be downloaded
Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended.

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below

Click here for more information on minimum system requirements.

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

PROVIDER STATEMENT

Provided by Integrity Continuing Education, Inc.

SUPPORTER ACKNOWLEDGEMENT

Supported by an educational grant from AbbVie Inc. Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Managing the IBD Patient: Delayed Post-Operative Recurrence of Crohn's Disease